ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 308

Nailfold Capillaroscopy in Patients with Early Onset-Dermatomyositis

Renata Miossi, Fernando Henrique Carlos de Souza and Samuel Katsuyuki Shinjo, Rheumatology Division, Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Dermatomyositis and nailfold capillaroscopy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Muscle Biology, Myositis and Myopathies Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Nailfold capillaroscopy (NC) has been demonstrated to be an important tool in the treatment of patients with juvenile dermatomyositis (JDM) and systemic sclerosis. However, NC has been scarcely studied in adult patients with DM. Therefore we analyzed NC specifically in adult patients with early onset-DM and also evaluated the possible correlation between NC abnormalities and clinical and activity parameters of DM.

Methods: The present cross-sectional single-center study included 39 consecutive adult patients with early onset-DM (Bohan & Peter, 1975) followed in our Rheumatology outpatient clinic. The early onset was defined as DM diagnosis up to 24 months. We excluded patients with diabetes mellitus, malignancy associated-DM, amyopathic DM or other autoimmune diseases. The NC was performed using Olympus®stereomicroscope. A semiquantitative rating scale was used to score capillaroscopy changes. Myositis disease activity assessment tools were used to assess disease activity [Manual Muscle Testing (MMT), Myositis Disease Activity Assessment Visual Analogue Scales (MYOACT), Health Assessment Questionnaire (HAQ), physician’s VAS, patient’s VAS, serum muscle enzymes levels].

Results: The median age of patients was 42.0 (interquartile range: 36.0-55.0) years, with 69.2% Caucasian and 71.8% female gender. The median time of DM diagnosis was 1.0 (0.0-1.0) year, whereas the time duration between symptoms onset and DM diagnosis was 4.0 (3.0-12.0) months. The results presented median value of 75 (62-80) for MMT, 1.00 (0.13-2.41) for HAQ, 4.5 (3.0-5.8) cm for physician’s VAS, 5.0 (2.0-6.0) cm for patient’s VAS, 11 (6-21) for MYOACT, 174 (95-598) U/L for creatine kinase and 6.0 (3.8-12.0) U/L for aldolase. Concerning treatment, 92.3% were using prednisone 40 (10-60) mg/day and 76.2% at least one immunosuppressive drug. Thirty-two (82.1%) patients had scleroderma capillary (SD)-like pattern in the NC [density of 6.2 (4.0-7.6) capillaries/mm; 43.6% with severe avascular areas; 15.4% with high degree of micro-hemorrhages; 87.2% with bushy capillaries; 87.2% with dilated capillaries; 61.5% with giant capillaries, 89.7% with neoangiogenesis). The SD-like pattern correlated positively with HAQ, patient’s and physician’s VAS. The capillary density correlated positively with “shawl” sign, patient’s and physician’s VAS, whereas the neoangiogenesis correlated positively with patient’s VAS, MMT, HAQ and serum creatine kinase levels (P<0.05). The micro-hemorrhages correlated negatively with pulmonary involvement, while dose of prednisone correlated negatively with SD-like pattern (P<0.05). No significant correlations between NC and other demographic, clinical and laboratory parameters were observed. 

Conclusion: Similarly to JDM, the NC may provide helpful information about patients with early onset-DM by: (a) contributing to an early diagnosis and (b) correlating with disease activity parameters. Additional investigations with larger series of patients and prospective studies may be useful to reinforce our data.


Disclosure: R. Miossi, None; F. H. C. de Souza, None; S. K. Shinjo, None.

To cite this abstract in AMA style:

Miossi R, de Souza FHC, Shinjo SK. Nailfold Capillaroscopy in Patients with Early Onset-Dermatomyositis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/nailfold-capillaroscopy-in-patients-with-early-onset-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nailfold-capillaroscopy-in-patients-with-early-onset-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology